Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olsson

Showing results (601-610 of 632) with videos related to

Pageof 64
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 24, 2005
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension studyH Holdaas, B Fellström, E Cole, et al.
International Journal of Clinical Practice|January 27, 2009
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaD Maccubbin, H E Bays, A G Olsson, et al.
Archives of Internal Medicine|October 14, 1996
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival StudyT R Pedersen, K Berg, T J Cook, et al.
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
The American Journal of Cardiology|August 3, 2000
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol loweringT R Pedersen, L Wilhelmsen, O Faergeman, et al.
JAMA Cardiology|October 27, 2017
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical TrialGregory G Schwartz, Christie M Ballantyne, Philip J Barter, et al.
American Heart Journal|January 14, 2020
Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trialTaufiq Salahuddin, John Kittelson, Jean-Claude Tardif, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 19, 2004
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT StudyAlan G Jardine, Hallvard Holdaas, Bengt Fellström, et al.
Atherosclerosis. Supplements|November 9, 2004
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998Terje R Pedersen, Anders G Olsson, Ole Faergeman, et al.
The American Journal of Cardiology|August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery diseaseOle Faergeman, Ingar Holme, Rana Fayyad, et al.
Pageof 64

Showing results (601-610 of 632) with videos related to

Sort By:
Pageof 64
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 24, 2005
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension studyH Holdaas, B Fellström, E Cole, et al.
International Journal of Clinical Practice|January 27, 2009
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaD Maccubbin, H E Bays, A G Olsson, et al.
Archives of Internal Medicine|October 14, 1996
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival StudyT R Pedersen, K Berg, T J Cook, et al.
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
The American Journal of Cardiology|August 3, 2000
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol loweringT R Pedersen, L Wilhelmsen, O Faergeman, et al.
JAMA Cardiology|October 27, 2017
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical TrialGregory G Schwartz, Christie M Ballantyne, Philip J Barter, et al.
American Heart Journal|January 14, 2020
Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trialTaufiq Salahuddin, John Kittelson, Jean-Claude Tardif, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 19, 2004
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT StudyAlan G Jardine, Hallvard Holdaas, Bengt Fellström, et al.
Atherosclerosis. Supplements|November 9, 2004
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998Terje R Pedersen, Anders G Olsson, Ole Faergeman, et al.
The American Journal of Cardiology|August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery diseaseOle Faergeman, Ingar Holme, Rana Fayyad, et al.
Pageof 64